Evidence map›Paper›PMID 40414891›Full record

ArticleInfectious diseases of poverty2025

Assessment of Plasmodium vivax transmission and asymptomatic carriage risk among artisanal gold miners in western French Guiana, 2014-2020.

Alice Sanna, Yann Lambert, Stéphane Pelleau, Lise Musset, Yassamine Lazrek, Louise Hureau, Hedley Cairo, Stephen Vreden, Michael White, Maylis Douine

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alice SannaCentre d'Investigation Clinique (Inserm 1424), Institut Santé des Populations en Amazonie, Centre Hospitalier de Cayenne, Cayenne, French Guiana. a.sanna33@gmail.com.ORCID http://orcid.org/0000-0003-2426-2315
Yann LambertCentre d'Investigation Clinique (Inserm 1424), Institut Santé des Populations en Amazonie, Centre Hospitalier de Cayenne, Cayenne, French Guiana.
Stéphane PelleauInfectious Disease Epidemiology and Analytics, Institut Pasteur, Université Paris Cité, Paris, France.
Lise MussetParasitology Laboratory, National Malaria Reference Center, Institut Pasteur de La Guyane, Cayenne, French Guiana.
Yassamine LazrekParasitology Laboratory, National Malaria Reference Center, Institut Pasteur de La Guyane, Cayenne, French Guiana.
Louise HureauCentre d'Investigation Clinique (Inserm 1424), Institut Santé des Populations en Amazonie, Centre Hospitalier de Cayenne, Cayenne, French Guiana.
Hedley CairoNational Malaria Programme, Ministry of Health, Paramaribo, Suriname.
Stephen VredenFoundation for the Advancement of Scientific Research in Suriname (SWOS), Paramaribo, Suriname.
Michael WhiteInfectious Disease Epidemiology and Analytics, Institut Pasteur, Université Paris Cité, Paris, France.
Maylis DouineCentre d'Investigation Clinique (Inserm 1424), Institut Santé des Populations en Amazonie, Centre Hospitalier de Cayenne, Cayenne, French Guiana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe final challenge for malaria elimination in many countries is to interrupt the circulation of Plasmodium vivax. Given the unique biology of this parasite, innovative approaches are imperative, with a focus on identifying asymptomatic carriers of dormant parasite forms. This article delineates the recent epidemiological patterns of P. vivax malaria within a highly mobile and hard-to-reach population in the Guiana Shield. It further proposes an assessment of the potential reservoir of asymptomatic carriers.

methodsThis analysis was based on data from: (i) two cross-sectional surveys carried out at the French-Surinamese border in 2015 and 2019, including adults returning from gold mining sites located in French Guiana (FG), [questionnaires and blood samples, tested for polymerase chain reaction (PCR) and P. vivax serological exposure markers (SEM) of recent infection]; (ii) epidemiological malaria surveillance system in Suriname, including cases imported from gold mining sites located in western FG between 2014 and 2020. Factors associated with P. vivax seropositivity were analysed by multiple logistic regression. The probability of carrying P. vivax parasites (blood-stage or hypnozoite) was estimated by a classification drawn from PCR results, SEM and reported recent history of illness.

resultsSurveillance data showed a decrease in malaria imported cases from French Guiana between beginning and end of the analysed period (236 in 2014 to 74 in 2020) and an increase in the proportion of cases associated with P. vivax (52.4% in 2014 to 100% in 2020). The PCR-prevalence of P. vivax in survey samples decreased from 11.4% in 2015 to 4.0% in 2019; P. vivax seropositivity decreased from 44.7% to 28.4%. P. vivax seropositivity was positively associated with male sex, age and number of years spent in gold mining, type of activity, and reported malaria history (episode within less than nine months OR = 10.73, 95% CI: 5.87-19.6, or history of repeated older episodes OR = 5.31, 95% CI: 3.13-9.01).

conclusionsOur analysis shows an epidemiological evolution typical of a scenario of decreasing malaria circulation. Nevertheless, in 2020, gold miners in western FG still showed a moderate level of P. vivax circulation. Biological methods and epidemiological criteria can help to select potential parasite carriers, who could benefit from targeted drug administration.

Indexed as

Carrier StateMalaria, VivaxMinersPlasmodium vivaxAdolescentAdultCross-Sectional StudiesFemaleFrench GuianaGoldHumansMaleMiddle AgedMiningPrevalenceYoung AdultGoldAsymptomatic carriageHard-to-reach populationIncidenceMalaria eliminationPlasmodium vivaxPrevalenceSerology

Identifiers

PMID40414891
PMCPMC12105214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.